由于成本上升,Biogen公司的收益超过了第一季度,但降低了2026年每股利预期. Biogen beat Q1 earnings but lowered 2026 EPS guidance due to higher costs.

生物公司报告第一季度的收益强于预期,但将其2026年经调整的每股利指标降至14.25-15.25美元,并引用了大约1.00美元的研究成本. Biogen reported stronger-than-expected first-quarter earnings but lowered its 2026 adjusted EPS guidance to $14.25-$15.25, citing approximately $1.00 in research costs. 该公司预计2026年收入将下降到单位数,原因是多发性硬化症和生物类似药销售量减少. The company anticipates mid-single digit revenue declines for 2026, driven by falling multiple sclerosis and biosimilar sales.